ID   OX2R_HUMAN              Reviewed;         444 AA.
AC   O43614; Q5VTM0;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 2.
DT   28-JUN-2023, entry version 177.
DE   RecName: Full=Orexin receptor type 2;
DE            Short=Ox-2-R;
DE            Short=Ox2-R;
DE            Short=Ox2R;
DE   AltName: Full=Hypocretin receptor type 2;
GN   Name=HCRTR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND VARIANT
RP   VAL-308.
RX   PubMed=9491897; DOI=10.1016/s0092-8674(00)80949-6;
RA   Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H.,
RA   Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.R.S.,
RA   Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E.,
RA   Liu W.-S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M.;
RT   "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G
RT   protein-coupled receptors that regulate feeding behavior.";
RL   Cell 92:573-585(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-10; THR-11; VAL-293 AND
RP   VAL-308.
RX   PubMed=11723285; DOI=10.1212/wnl.57.10.1896;
RA   Olafsdottir B.R., Rye D.B., Scammell T.E., Matheson J.K., Stefansson K.,
RA   Gulcher J.R.;
RT   "Polymorphisms in hypocretin/orexin pathway genes and narcolepsy.";
RL   Neurology 57:1896-1899(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   REVIEW.
RX   PubMed=11340621; DOI=10.1002/bies.1058;
RA   Hungs M., Mignot E.;
RT   "Hypocretin/orexin, sleep and narcolepsy.";
RL   Bioessays 23:397-408(2001).
RN   [6]
RP   REVIEW.
RX   PubMed=11283317; DOI=10.1146/annurev.neuro.24.1.429;
RA   Willie J.T., Chemelli R.M., Sinton C.M., Yanagisawa M.;
RT   "To eat or to sleep? Orexin in the regulation of feeding and wakefulness.";
RL   Annu. Rev. Neurosci. 24:429-458(2001).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, MUTAGENESIS OF 33-ASP--HIS-49;
RP   TRP-44 AND ASN-324, AND DOMAIN.
RX   PubMed=26950369; DOI=10.1038/nsmb.3183;
RA   Yin J., Babaoglu K., Brautigam C.A., Clark L., Shao Z., Scheuermann T.H.,
RA   Harrell C.M., Gotter A.L., Roecker A.J., Winrow C.J., Renger J.J.,
RA   Coleman P.J., Rosenbaum D.M.;
RT   "Structure and ligand-binding mechanism of the human OX1 and OX2 orexin
RT   receptors.";
RL   Nat. Struct. Mol. Biol. 23:293-299(2016).
RN   [8] {ECO:0007744|PDB:4S0V}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 3-254 AND 294-388 IN COMPLEX WITH
RP   THE INHIBITOR SUVOREXANT, TOPOLOGY, SUBCELLULAR LOCATION, AND DISULFIDE
RP   BONDS.
RX   PubMed=25533960; DOI=10.1038/nature14035;
RA   Yin J., Mobarec J.C., Kolb P., Rosenbaum D.M.;
RT   "Crystal structure of the human OX2 orexin receptor bound to the insomnia
RT   drug suvorexant.";
RL   Nature 519:247-250(2015).
RN   [9] {ECO:0007744|PDB:7L1U, ECO:0007744|PDB:7L1V}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.00 ANGSTROMS) OF 3-389 IN COMPLEX WITH
RP   HCRT 70-97.
RX   PubMed=33547286; DOI=10.1038/s41467-021-21087-6;
RA   Hong C., Byrne N.J., Zamlynny B., Tummala S., Xiao L., Shipman J.M.,
RA   Partridge A.T., Minnick C., Breslin M.J., Rudd M.T., Stachel S.J.,
RA   Rada V.L., Kern J.C., Armacost K.A., Hollingsworth S.A., O'Brien J.A.,
RA   Hall D.L., McDonald T.P., Strickland C., Brooun A., Soisson S.M.,
RA   Hollenstein K.;
RT   "Structures of active-state orexin receptor 2 rationalize peptide and
RT   small-molecule agonist recognition and receptor activation.";
RL   Nat. Commun. 12:815-815(2021).
CC   -!- FUNCTION: Nonselective, high-affinity receptor for both orexin-A and
CC       orexin-B neuropeptides (PubMed:9491897, PubMed:26950369). Triggers an
CC       increase in cytoplasmic Ca(2+) levels in response to orexin-A binding
CC       (PubMed:9491897, PubMed:26950369). {ECO:0000269|PubMed:26950369,
CC       ECO:0000269|PubMed:9491897}.
CC   -!- INTERACTION:
CC       O43614; P62937: PPIA; NbExp=3; IntAct=EBI-25884102, EBI-437708;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26950369,
CC       ECO:0000269|PubMed:9491897, ECO:0000305|PubMed:25533960}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:25533960}.
CC   -!- DOMAIN: The N-terminal region is required for orexin signaling.
CC       {ECO:0000269|PubMed:26950369}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF041245; AAC39602.1; -; mRNA.
DR   EMBL; AY062031; AAL47215.1; -; Genomic_DNA.
DR   EMBL; AL591718; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL449104; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX04440.1; -; Genomic_DNA.
DR   CCDS; CCDS4956.1; -.
DR   RefSeq; NP_001517.2; NM_001526.4.
DR   PDB; 4S0V; X-ray; 2.50 A; A=3-254, A=294-388.
DR   PDB; 5WQC; X-ray; 1.96 A; A=3-254, A=294-386.
DR   PDB; 5WS3; X-ray; 2.30 A; A=3-254, A=294-388.
DR   PDB; 6TPG; X-ray; 2.74 A; A=1-254, A=294-307.
DR   PDB; 6TPJ; X-ray; 2.74 A; A/B=1-254, A/B=294-307.
DR   PDB; 6TPN; X-ray; 2.61 A; A=1-254, A=294-388.
DR   PDB; 7L1U; EM; 3.20 A; R=3-389.
DR   PDB; 7L1V; EM; 3.00 A; R=3-389.
DR   PDB; 7SQO; EM; 3.17 A; R=1-444.
DR   PDB; 7XRR; X-ray; 2.89 A; A=33-394.
DR   PDBsum; 4S0V; -.
DR   PDBsum; 5WQC; -.
DR   PDBsum; 5WS3; -.
DR   PDBsum; 6TPG; -.
DR   PDBsum; 6TPJ; -.
DR   PDBsum; 6TPN; -.
DR   PDBsum; 7L1U; -.
DR   PDBsum; 7L1V; -.
DR   PDBsum; 7SQO; -.
DR   PDBsum; 7XRR; -.
DR   AlphaFoldDB; O43614; -.
DR   SMR; O43614; -.
DR   BioGRID; 109312; 35.
DR   IntAct; O43614; 1.
DR   STRING; 9606.ENSP00000477548; -.
DR   BindingDB; O43614; -.
DR   ChEMBL; CHEMBL4792; -.
DR   DrugBank; DB15031; Daridorexant.
DR   DrugBank; DB11951; Lemborexant.
DR   DrugBank; DB09034; Suvorexant.
DR   DrugCentral; O43614; -.
DR   GuidetoPHARMACOLOGY; 322; -.
DR   GlyCosmos; O43614; 3 sites, No reported glycans.
DR   GlyGen; O43614; 3 sites.
DR   iPTMnet; O43614; -.
DR   PhosphoSitePlus; O43614; -.
DR   BioMuta; HCRTR2; -.
DR   EPD; O43614; -.
DR   MassIVE; O43614; -.
DR   PaxDb; O43614; -.
DR   PeptideAtlas; O43614; -.
DR   Antibodypedia; 17332; 382 antibodies from 38 providers.
DR   DNASU; 3062; -.
DR   Ensembl; ENST00000370862.4; ENSP00000359899.3; ENSG00000137252.10.
DR   Ensembl; ENST00000615358.4; ENSP00000477548.1; ENSG00000137252.10.
DR   GeneID; 3062; -.
DR   KEGG; hsa:3062; -.
DR   MANE-Select; ENST00000370862.4; ENSP00000359899.3; NM_001384272.1; NP_001371201.1.
DR   AGR; HGNC:4849; -.
DR   CTD; 3062; -.
DR   DisGeNET; 3062; -.
DR   GeneCards; HCRTR2; -.
DR   HGNC; HGNC:4849; HCRTR2.
DR   HPA; ENSG00000137252; Tissue enriched (brain).
DR   MIM; 602393; gene.
DR   neXtProt; NX_O43614; -.
DR   OpenTargets; ENSG00000137252; -.
DR   PharmGKB; PA29223; -.
DR   VEuPathDB; HostDB:ENSG00000137252; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01070000253744; -.
DR   HOGENOM; CLU_009579_6_3_1; -.
DR   InParanoid; O43614; -.
DR   OMA; EWDKFVP; -.
DR   OrthoDB; 2949325at2759; -.
DR   PhylomeDB; O43614; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; O43614; -.
DR   Reactome; R-HSA-389397; Orexin and neuropeptides FF and QRFP bind to their respective receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SignaLink; O43614; -.
DR   SIGNOR; O43614; -.
DR   BioGRID-ORCS; 3062; 15 hits in 1144 CRISPR screens.
DR   ChiTaRS; HCRTR2; human.
DR   GeneWiki; Hypocretin_(orexin)_receptor_2; -.
DR   GenomeRNAi; 3062; -.
DR   Pharos; O43614; Tclin.
DR   PRO; PR:O43614; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; O43614; protein.
DR   Bgee; ENSG00000137252; Expressed in cortical plate and 37 other tissues.
DR   ExpressionAtlas; O43614; baseline and differential.
DR   Genevisible; O43614; HS.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0008188; F:neuropeptide receptor activity; TAS:ProtInc.
DR   GO; GO:0016499; F:orexin receptor activity; IDA:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IEA:Ensembl.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IBA:GO_Central.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0022410; P:circadian sleep/wake cycle process; IEA:InterPro.
DR   GO; GO:0007631; P:feeding behavior; TAS:ProtInc.
DR   GO; GO:0040011; P:locomotion; IEA:Ensembl.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0010840; P:regulation of circadian sleep/wake cycle, wakefulness; ISS:UniProtKB.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   CDD; cd15208; 7tmA_OXR; 1.
DR   Gene3D; 1.20.1070.10; Rhodopsin 7-helix transmembrane proteins; 1.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000204; Orexin_rcpt.
DR   InterPro; IPR004060; Orexin_rcpt_2.
DR   PANTHER; PTHR45695:SF15; G PROTEIN-COUPLED RECEPTOR 15-LIKE; 1.
DR   PANTHER; PTHR45695; LEUCOKININ RECEPTOR-RELATED; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF03827; Orexin_rec2; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01522; OREXIN2R.
DR   PRINTS; PR01064; OREXINR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   SUPFAM; SSF81321; Family A G protein-coupled receptor-like; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..444
FT                   /note="Orexin receptor type 2"
FT                   /id="PRO_0000069989"
FT   TOPO_DOM        1..54
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25533960,
FT                   ECO:0000305|PubMed:26950369"
FT   TRANSMEM        55..75
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        76..88
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        89..110
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        111..127
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        128..150
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        151..170
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        171..191
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        192..222
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        223..243
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        244..304
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        305..326
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        327..342
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        343..366
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        367..444
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   REGION          1..20
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          33..49
FT                   /note="Required for response to orexin-A"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   BINDING         324
FT                   /ligand="suvorexant"
FT                   /ligand_id="ChEBI:CHEBI:82698"
FT                   /ligand_note="antagonist"
FT                   /evidence="ECO:0000269|PubMed:25533960,
FT                   ECO:0007744|PDB:4S0V"
FT   SITE            44
FT                   /note="Important for responses to orexin"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   CARBOHYD        14
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        22
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        202
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        127..210
FT                   /evidence="ECO:0007744|PDB:4S0V"
FT   VARIANT         10
FT                   /note="P -> S (in dbSNP:rs41271310)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_044507"
FT   VARIANT         11
FT                   /note="P -> T (in dbSNP:rs41271312)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_044508"
FT   VARIANT         293
FT                   /note="I -> V (in dbSNP:rs74720027)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_044509"
FT   VARIANT         308
FT                   /note="I -> V (in dbSNP:rs2653349)"
FT                   /evidence="ECO:0000269|PubMed:11723285,
FT                   ECO:0000269|PubMed:9491897"
FT                   /id="VAR_044510"
FT   MUTAGEN         33..49
FT                   /note="Missing: Abolishes response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   MUTAGEN         44
FT                   /note="W->N: Abolishes response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   MUTAGEN         324
FT                   /note="N->A: Strongly impairs response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   HELIX           40..47
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           54..81
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           83..85
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           88..106
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           108..117
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           123..156
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   STRAND          158..160
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           166..183
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           185..190
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   STRAND          191..196
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   STRAND          199..202
FT                   /evidence="ECO:0007829|PDB:5WS3"
FT   STRAND          207..212
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   STRAND          215..217
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           218..231
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           233..251
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   TURN            252..254
FT                   /evidence="ECO:0007829|PDB:6TPN"
FT   HELIX           294..328
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   TURN            332..335
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           339..367
FT                   /evidence="ECO:0007829|PDB:5WQC"
FT   HELIX           369..381
FT                   /evidence="ECO:0007829|PDB:5WQC"
SQ   SEQUENCE   444 AA;  50694 MW;  C4C9A153D42254C6 CRC64;
     MSGTKLEDSP PCRNWSSASE LNETQEPFLN PTDYDDEEFL RYLWREYLHP KEYEWVLIAG
     YIIVFVVALI GNVLVCVAVW KNHHMRTVTN YFIVNLSLAD VLVTITCLPA TLVVDITETW
     FFGQSLCKVI PYLQTVSVSV SVLTLSCIAL DRWYAICHPL MFKSTAKRAR NSIVIIWIVS
     CIIMIPQAIV MECSTVFPGL ANKTTLFTVC DERWGGEIYP KMYHICFFLV TYMAPLCLMV
     LAYLQIFRKL WCRQIPGTSS VVQRKWKPLQ PVSQPRGPGQ PTKSRMSAVA AEIKQIRARR
     KTARMLMIVL LVFAICYLPI SILNVLKRVF GMFAHTEDRE TVYAWFTFSH WLVYANSAAN
     PIIYNFLSGK FREEFKAAFS CCCLGVHHRQ EDRLTRGRTS TESRKSLTTQ ISNFDNISKL
     SEQVVLTSIS TLPAANGAGP LQNW
//
